PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18047631-3 2008 The aim of the present study was to test whether PPAR-gamma agonists 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2) and pioglitazone could alter AngII-induced collagen type I formation in vascular adventitial fibroblasts via reactive oxygen species (ROS). Pioglitazone 125-137 angiotensinogen Rattus norvegicus 150-155 18246090-7 2008 In FDR pioglitazone diminished the augmented vasoconstrictor responses to SCS, noradrenaline and angiotensin II, and ameliorated the decrease in vasodilator responses to SCS. Pioglitazone 7-19 angiotensinogen Rattus norvegicus 97-111 18047631-13 2008 Pretreatment of cells with 15d-PGJ2 and pioglitazone attenuated collagen type I expression and generation of ROS induced by AngII, respectively. Pioglitazone 40-52 angiotensinogen Rattus norvegicus 124-129 18047631-15 2008 Angiotensin II treatment activated the redox-sensitive transcription factors NF-kappaB and AP-1, whereas pretreatment with 15d-PGJ2 and pioglitazone reduced the AngII-induced DNA-binding activity of NF-kappaB but not AP-1. Pioglitazone 136-148 angiotensinogen Rattus norvegicus 161-166 18047631-16 2008 4 Our data demonstrate that the PPAR-gamma agonists 15d-PGJ2 and pioglitazone attenuate AngII-mediated collagen type I expression in adventitial fibroblasts, which may be mediated by the modulation of ROS release and the redox-sensitive transcription factor NF-kappaB. Pioglitazone 65-77 angiotensinogen Rattus norvegicus 88-93 16835400-0 2006 The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats. Pioglitazone 22-34 angiotensinogen Rattus norvegicus 64-78 16835400-9 2006 Pioglitazone blunted the systemic response to ANG II and abolished the increased responsiveness to ANG II induced by a HS diet. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 46-52 16835400-9 2006 Pioglitazone blunted the systemic response to ANG II and abolished the increased responsiveness to ANG II induced by a HS diet. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 99-105 16835400-10 2006 Pioglitazone modified the renal hemodynamic response to changes in salt intake while maintaining a lower filtration fraction with ANG II perfusion. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 130-136 16835400-12 2006 In conclusion, these data demonstrate that the peroxisome proliferator-activated receptor-gamma agonist pioglitazone modifies the physiological relationship between sodium chloride and the response to ANG II in insulin-resistant rats. Pioglitazone 104-116 angiotensinogen Rattus norvegicus 201-207 15308580-3 2004 In cultured rat aortic smooth muscle cells (RASMC), Rho kinase stimulated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone, and these effects were explained by the inhibition of the Rho translocation to the cell membrane. Pioglitazone 132-144 angiotensinogen Rattus norvegicus 77-91 15828239-3 2005 In cultured rat aortic smooth muscle cells, Rho kinase activated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone. Pioglitazone 123-135 angiotensinogen Rattus norvegicus 68-82 21166160-7 2005 RESULTS: Pioglitazone inhibited ANP and BNP mRNA expression and 3H-leucine incorporation in neonatal rat cardiac myocytes induced by angiotensin II in a dose-dependent manner in vitro. Pioglitazone 9-21 angiotensinogen Rattus norvegicus 133-147 21162229-4 2006 RESULTS: Angiotensin II caused a significant increase in MTT value and 3H-TdR uptake in CNM, which could be significantly reversed by pioglitazone and 15d-PGJ2 in a dose-dependent manner. Pioglitazone 134-146 angiotensinogen Rattus norvegicus 9-23 15308580-9 2004 Finally, both basal and angiotensin II-stimulated levels of Rho kinase activity were greater in RASMC from SHR than those from WKY, and the enhanced Rho kinase activity was blocked by pioglitazone or troglitazone in both strains. Pioglitazone 184-196 angiotensinogen Rattus norvegicus 24-38 27012965-0 2016 The bioflavonoid quercetin synergises with PPAR-gamma agonist pioglitazone in reducing angiotensin-II contractile effect in fructose-streptozotocin induced diabetic rats. Pioglitazone 62-74 angiotensinogen Rattus norvegicus 87-101 8780234-3 1996 In vivo, pretreatment with pioglitazone inhibited (P < 0.02) pressor responses to both norepinephrine and angiotensin II in conscious Dahl-S, but not in Sprague-Dawley rats. Pioglitazone 27-39 angiotensinogen Rattus norvegicus 109-123 29716851-8 2018 Pioglitazone significantly decreased responses to NA, PE, ME and ANG II in ND-PIO versus ND-CON by 63%. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 65-71 34973951-8 2022 Responses to intra-renal administration of adrenergic agonists including noradrenaline (NA), phenylephrine (PE), methoxamine (ME), and angiotensin-II (ANG-II) were larger in diabetic WKY, but significantly blunted with adiponectin treatment in diabetic WKYs to 35-40%, and further reduced by 65-70% in combination with pioglitazone. Pioglitazone 319-331 angiotensinogen Rattus norvegicus 135-149 34973951-8 2022 Responses to intra-renal administration of adrenergic agonists including noradrenaline (NA), phenylephrine (PE), methoxamine (ME), and angiotensin-II (ANG-II) were larger in diabetic WKY, but significantly blunted with adiponectin treatment in diabetic WKYs to 35-40%, and further reduced by 65-70% in combination with pioglitazone. Pioglitazone 319-331 angiotensinogen Rattus norvegicus 151-157 29972411-8 2018 RESULTS: Pioglitazone and VEGFR-2-selective inhibitor apatinib reduced rat cardiomyocyte viability and cardiomyocyte hypertrophy induced by angiotensin II in vitro. Pioglitazone 9-21 angiotensinogen Rattus norvegicus 140-154 27012965-1 2016 This study investigated the effects of combined minimal concentrations of quercetin and pioglitazone on angiotensin II-induced contraction of the aorta from fructose-streptozotocin (F-STZ)-induced type 2 diabetic rats and the possible role of superoxide anions (O2(-)) and nitric oxide (NO) in their potential therapeutic interaction. Pioglitazone 88-100 angiotensinogen Rattus norvegicus 104-118 26156624-0 2015 Pioglitazone Reduces Vascular Lipid Accumulation in Angiotensin II-Induced Hypertensive Rat. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 52-66 26101342-9 2015 These responses to angiotensin II were exacerbated by GW9662 and ameliorated by pioglitazone, which increased PPAR-gamma mRNA and PPAR-gamma DNA-binding activity in subfornical organ and hypothalamic paraventricular nucleus. Pioglitazone 80-92 angiotensinogen Rattus norvegicus 19-33 26156624-3 2015 In the current study, we analyzed whether pioglitazone, an agonist of PPARgamma, reduces angiotensin II-induced vascular lipid accumulation. Pioglitazone 42-54 angiotensinogen Rattus norvegicus 89-103 26156624-6 2015 RESULTS: Pioglitazone significantly reduced angiotensin II-induced enhanced lipid deposition and superoxide production in the adventitia of the aorta, as detected by oil red O and dihydroethidium (DHE) staining, respectively. Pioglitazone 9-21 angiotensinogen Rattus norvegicus 44-58 24727493-0 2014 Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 21-35 26156624-8 2015 Angiotensin II-induced upregulation of the expression of LDL receptor and Nox1 was inhibited by pioglitazone treatment. Pioglitazone 96-108 angiotensinogen Rattus norvegicus 0-14 26156624-9 2015 In addition, angiotensin II significantly reduced the expression of PCSK9, and this reduction was ameliorated by pioglitazone. Pioglitazone 113-125 angiotensinogen Rattus norvegicus 13-27 26156624-10 2015 On the other hand, pioglitazone did not significantly alter the expression of the phosphorylated forms of AMPKalpha and ACC, which was downregulated by angiotensin II. Pioglitazone 19-31 angiotensinogen Rattus norvegicus 152-166 26156624-11 2015 CONCLUSIONS: Pioglitazone treatment suppressed excess lipid accumulation and superoxide production in the aorta in an angiotensin II-induced rat model of hypertension. Pioglitazone 13-25 angiotensinogen Rattus norvegicus 118-132 24727493-9 2014 Pioglitazone reduced the effects of ANG II on NOX activity, NOX-1, pre-pro-ET-1, COX-2, and c-Jun mRNA levels, JNK activation, and nuclear phospho-c-Jun and p65 expression. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 36-42 24727493-11 2014 Furthermore, pioglitazone inhibits ANG II-induced COX-2 expression likely by interfering with NF-kappaB and activator protein-1 proinflammatory pathways and downregulating ROS production and ET-1 transcription, thus contributing to the anti-inflammatory properties of glitazones. Pioglitazone 13-25 angiotensinogen Rattus norvegicus 35-41 23676251-0 2014 Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 100-114 23676251-8 2014 Combination therapy of losartan and pioglitazone reduced BP more than either monotherapy, and showed additive effects on improving endothelial dysfunction and abolishing the increased vascular responsiveness to angiotensin II. Pioglitazone 36-48 angiotensinogen Rattus norvegicus 211-225 24114819-9 2013 Pioglitazone significantly reduced the concentrations of serum lipid, aminotransaminase, glucose, insulin, ACE, angiotensin II while markedly raised the concentrations of serum ACE2, angiotensin-(1-7) and the degree of hepatic ACE2 expression. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 112-126 22277574-0 2013 Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 84-98 22277574-2 2013 In the current study, we examined the effect of pioglitazone, an agonist of peroxisome proliferator activated receptor-gamma, on angiotensin II-induced intracardiac lipid accumulation and cardiac dysfunction. Pioglitazone 48-60 angiotensinogen Rattus norvegicus 129-143 22277574-3 2013 Pioglitazone, given orally at a dose of 2.5mg/kg/d, reduced cardiac triglyceride content and suppressed lipid deposition in the heart of angiotensin II-induced hypertensive rats without affecting angiotensin II-induced upregulation of lipogenic gene expression. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 137-151 22277574-4 2013 Histological examination showed that pioglitazone reduced the area of cardiac fibrosis and iron deposition in the heart of angiotensin II-treated rats. Pioglitazone 37-49 angiotensinogen Rattus norvegicus 123-137 22277574-6 2013 Angiotensin II increased the superoxide signals detected by dihydroethidium staining in myocardial cells with lipid deposition, and this increase was suppressed by pioglitazone. Pioglitazone 164-176 angiotensinogen Rattus norvegicus 0-14 22277574-8 2013 It was found that pioglitazone improved both the systolic and diastolic cardiac performance, which was weakened by angiotensin II infusion, after transient ischemia and reperfusion. Pioglitazone 18-30 angiotensinogen Rattus norvegicus 115-129 22277574-9 2013 These findings collectively suggest that pioglitazone treatment ameliorated the histological and functional cardiac damage induced by angiotensin II infusion, the mechanism of which may be related to the antioxidative action of pioglitazone. Pioglitazone 41-53 angiotensinogen Rattus norvegicus 134-148 22277574-9 2013 These findings collectively suggest that pioglitazone treatment ameliorated the histological and functional cardiac damage induced by angiotensin II infusion, the mechanism of which may be related to the antioxidative action of pioglitazone. Pioglitazone 228-240 angiotensinogen Rattus norvegicus 134-148 23633075-5 2013 Pioglitazone increased the expression of miR-711 in cardiac fibroblasts, and overexpression of miR-711 suppressed collagen-I levels in angiotensin II (Ang II)-treated or untreated cells. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 151-157 22387860-3 2012 Here we have examined the effect of pioglitazone, an agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), on renal lipid accumulation and renal injury induced by angiotensin II infusion. Pioglitazone 36-48 angiotensinogen Rattus norvegicus 187-201 22387860-4 2012 Pioglitazone treatment (2.5mg/kg/day) reduced the amount of triglycerides in the kidney of the angiotensin II-induced hypertensive rat without significantly altering either blood pressure levels or mRNA expression of lipogenic genes in the kidney. Pioglitazone 0-12 angiotensinogen Rattus norvegicus 95-109 22387860-5 2012 In addition, pioglitazone, either alone or in conjunction with angiotensin II, increased the expression of phosphorylated, but not total, AMP-activated protein kinase (AMPK). Pioglitazone 13-25 angiotensinogen Rattus norvegicus 63-77 22387860-6 2012 Proteinuria and kidney weight in the angiotensin II-infused rat were significantly decreased by pioglitazone treatment. Pioglitazone 96-108 angiotensinogen Rattus norvegicus 37-51 22387860-8 2012 These findings suggested that pioglitazone suppressed the angiotensin II-induced increase in renal lipid content by inhibiting its proteinuric action, but not by direct alteration of the expression or activity of lipid metabolism-related genes. Pioglitazone 30-42 angiotensinogen Rattus norvegicus 58-72 22031275-10 2012 Myocardial expression of angiotensin II and AT1 receptor protein in HF group was higher when compared with the control and pioglitazone groups (P < .01). Pioglitazone 123-135 angiotensinogen Rattus norvegicus 25-39 21291492-10 2011 In vitro, AngII upregulated the expression of sEH and hypertrophy markers, including atrial natriuretic factor and beta-myosin heavy chain, in rat neonatal cardiomyocytes and H9c2 cells, which was attenuated by rosiglitazone and pioglitazone. Pioglitazone 229-241 angiotensinogen Rattus norvegicus 10-15